Background: Six cholinesterase inhibitors (ChEIs) have been tested in people with
Alzheimer's disease, using methods currently required for regulatory approval. The clinical …

The traditional aim of Alzheimer's disease treatment in clinical trials has been to improve
cognitive abilities. It has become increasingly clear, however, that other aspects are …

Background: Currently approved Alzheimer's disease (AD) treatments have been reported to
provide symptomatic benefit, without proven impact on clinical progression. We …

Background: To evaluate efficacy and safety of galantamine for patients with vascular
dementia (VaD). Methods: In this multinational, randomized, double-blind, placebo …

Objectives: To understand the treatment goals of Alzheimer's disease (AD) patients, carers,
and physicians; to estimate whether clinically important goals are met during treatment with …

Background In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's
Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically …

Introduction: Alzheimer disease (AD) is a progressive neurodegenerative disorder
characterized by severe cognitive impairment, inability to perform activities of daily living and …

Background Donepezil is a first-line drug for the treatment of Alzheimer's disease (AD).
However, there are no meta-analyses on efficacy and safety of high-dose versus standard …

Dementia is rapidly increasing as the global population ages and is projected to make an
enormous impact on all societies. AD is the most common form of dementia, accounting for …

Background: Donepezil is an established treatment for mild, moderate, and severe
Alzheimer's disease (AD). An international study demonstrated superior efficacy of sustained …